Evommune (EVMN) Share-based Compensation (2024 - 2026)

Evommune (EVMN) has reported Share-based Compensation for 3 consecutive years, with $35.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation changed N/A year-over-year to $35.9 million; the TTM figure through Mar 2026 stood at $35.9 million (changed N/A YoY), while the FY2025 annual figure was $38.6 million, up 2141.58% from the prior year.
• Share-based Compensation grew to $35.9 million in Q1 2026 per EVMN's latest filing, from $1.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $35.9 million in Q1 2026 and bottomed at $401000.0 in Q3 2024.
• Historically, Share-based Compensation has averaged $8.7 million across 3 years, with a median of $1.1 million in 2025.
• On a YoY basis, Share-based Compensation climbed as much as 39.9% in 2025 and fell as far as 80.02% in 2025.
• Evommune's Share-based Compensation stood at $5.5 million in 2024, then plunged by 80.02% to $1.1 million in 2025, then surged by 3166.61% to $35.9 million in 2026.
• Business Quant data shows EVMN's Share-based Compensation at $35.9 million in Q1 2026, $1.1 million in Q4 2025, and $561000.0 in Q3 2025.